Oncology Startups

One Health operates a clinical trial platform using canine cancer data to accelerate and de-risk human oncology drug development. The company leverages a dataset of 2 billion datapoints from dogs with naturally occurring cancer to serve as a comparative model for pharmaceutical R&D, helping drug developers validate efficacy and identify biomarkers before human trials.

12 investors

Kopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.

6 investors

Notable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.

6 investors

Granza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.

5 investors

CCG.ai develops software that uses clinical and genomic data to help oncologists select appropriate cancer treatments for individual patients, with a focus on identifying predictive biomarkers linked to treatment response.

4 investors

Numerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.

4 investors

Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.

4 investors

Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.

3 investors

Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

2 investors

Clear Gene develops RNA diagnostics for detecting residual solid tumors in cancer patients and provides software and reagent kits to help clinical laboratories process COVID-19 samples more efficiently using existing equipment.

2 investors

Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.

2 investors

Adventris is a biotechnology company developing cancer immunotherapy treatments.

1 investor

Eris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.

1 investor

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

1 investor

Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.

1 investor

Known Medicine develops a predictive engine using AI and patient datasets to identify optimal cancer treatments for individual patients. The company serves oncologists and cancer patients through computational analysis of biomaterials and drug-discovery data.

1 investor

Omanta provides personalized scientific research support for complex disease cases, assigning PhD-level teams to build detailed molecular profiles from a patient's genomic, RNA, and protein data. It cross-references each patient's molecular profile against an internal reference cohort and biomedical literature to model therapeutic options and produce a research roadmap that informs the clinical team's decisions.</parameter> <parameter name="founders">[]

1 investor

Oncobox provides genetic profiling of tumor samples to help oncologists select the most likely effective drug from existing targeted cancer therapies for individual patients with advanced cancer. The analysis examines tumor DNA, RNA, and molecular pathways to identify the most relevant drug targets and generates a clinical report recommending which treatments are most likely to work.

1 investor

REPROSENT captures patient treatment experience data to support dose, safety, and development decisions in oncology and advanced cancer therapies. The platform operates as a lightweight, non-interventional overlay on existing clinical trials and care programs, converting patient symptoms into structured, computable signal for development and clinical teams.

1 investor

SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.

1 investor

Zealth develops remote monitoring software that enables hospitals to track cancer patients after discharge and provide continuous automated support for managing treatment side effects and symptoms at home.

1 investor